Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
429 participants
INTERVENTIONAL
2018-11-01
2019-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Tailored Bowel Preparation Strategy Guided by a Predictive Model
NCT03142854
Efficacy of Tailored Bowel Preparation Strategy: A Randomized Controlled Study
NCT03765216
Efficacy of Prokinetics With Split Dose of PEG in Morning Colonoscopic Bowel Preparation
NCT01513096
Improved Bowel Preparation Method for Colonoscopy Based on Different Risk Stratification
NCT04582942
Low Volume PEG With Low Residue Test Meals Versus High Volume Split-dose PEG Bowel Preparation
NCT01568814
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tailored Group
In the tailored group, high-risk patients are instructed to drink the first 2 L of Polyethylene Glycol (PEG) at 19:00-21:00 hours on the day before colonoscopy at a rate of 250 ml every 15 min. On the day of the procedure, they take another 2 L PEG 4-6 h before colonoscopy. The low-risk patients were given a standard dose of 2 L PEG 4-6 h before colonoscopy.
Polyethylene Glycol
In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.
In the control group, all the patients are given routine regimens.
Control Group
In the control group, all the patients drink single dose of 2 l Polyethylene Glycol (PEG) 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
Polyethylene Glycol
In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.
In the control group, all the patients are given routine regimens.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polyethylene Glycol
In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.
In the control group, all the patients are given routine regimens.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* compromised swallowing reflex or mental status
* severe chronic renal failure(creatinine clearance \< 30 ml/min)
* severe congestive heart failure (New York Heart Association class III or IV)
* uncontrolled hypertension (systolic blood pressure \> 170 mm Hg, diastolic blood pressure \> 100 mm Hg)
* dehydration
* disturbance of electrolytes
* pregnancy or lactation
* hemodynamically unstable
* unable to give informed consent
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiuli Zuo
director of Qilu Hospital gastroenterology department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiuli Zuo, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Qilu Hospital of Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu Hospital of Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018SDU-QILU-G111
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.